We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.

User:Jaime.Prilusky/Test/Sortable

From Proteopedia

Revision as of 08:48, 18 October 2018 by Jaime Prilusky (Talk | contribs)
Jump to: navigation, search

Welcome to Proteopedia
ISSN 2310-6301 The free, collaborative 3D-encyclopedia of proteins & other molecules

Selected Pages Art on Science Journals Education
About this image
Coronavirus Spike Protein Membrane Fusion

by Eric Martz
SARS-CoV-2 spike protein "spears" the host membrane with a fusion peptide and drags the virus envelope membrane transmembrane domain close to the host membrane, initiating fusion. This moves the virus RNA genome into the host cell, initiating infection.
>>> Visit this page >>>

About this image
Opening a Gate to Human Health

by Alice Clark (PDBe)
In the 1970s, an exciting discovery of a family of medicines was made by the Japanese scientist Satoshi Ōmura. One of these molecules, ivermectin, is shown in this artwork bound in the ligand binding pocket of the Farnesoid X receptor, a protein which helps regulate cholesterol in humans. This structure showed that ivermectin induced transcriptional activity of FXR and could be used to regulate metabolism.

>>> Visit this page >>>

About this image
Interconversion of the specificities of human lysosomal enzymes associated with Fabry and Schindler diseases.

IB Tomasic, MC Metcalf, AI Guce, NE Clark, SC Garman. J. Biol. Chem. 2010 doi: 10.1074/jbc.M110.118588
The human lysosomal enzymes α-galactosidase and α-N-acetylgalactosaminidase share 46% amino acid sequence identity and have similar folds. Using a rational protein engineering approach, we interconverted the enzymatic specificity of α-GAL and α-NAGAL. The engineered α-GAL retains the antigenicity but has acquired the enzymatic specificity of α-NAGAL. Conversely, the engineered α-NAGAL retains the antigenicity but has acquired the enzymatic specificity of the α-GAL enzyme. Comparison of the crystal structures of the designed enzyme to the wild-type enzymes shows that active sites superimpose well, indicating success of the rational design. The designed enzymes might be useful as non-immunogenic alternatives in enzyme replacement therapy for treatment of lysosomal storage disorders such as Fabry disease.

>>> Visit this I3DC complement >>>

About this image
Tutorial: Ramachandran Plot Inspection

by Angel Herráez
Side-by-side display of dihedral angles in a 3D model of a tripeptide and its Ramachandran plot. Users can interact with any of them and the other will change accordingly. Includes animated rotations with display of clashes.

>>> Visit this page >>>

Proteopedia Page Contributors and Editors (what is this?)

Jaime Prilusky

Personal tools